Novel therapeutic approaches to autosomal dominant polycystic kidney disease

Area of Science:

• Nephrology
• Genetics
• Pharmacology

Background:

• Autosomal dominant polycystic kidney disease (ADPKD) is a prevalent inherited disorder leading to progressive renal cyst development and kidney failure.
• Currently, no FDA-approved treatments exist, with care being mainly supportive.
• ADPKD is a leading global cause of end-stage renal disease.

Purpose of the Study:

• To review the molecular biology underlying ADPKD.
• To examine the rationale for developing targeted molecular therapies.
• To assess the clinical evidence for novel ADPKD treatments.

Main Methods:

• Literature review of preclinical models and clinical trials.
• Analysis of molecular pathways implicated in ADPKD.
• Examination of drug classes such as vasopressin receptor antagonists and somatostatin analogs.

Main Results:

• Advances in understanding ADPKD molecular mechanisms.
• Promising preclinical and clinical trial data for novel therapies.
• Identification of specific drug candidates with potential to slow disease progression.

Conclusions:

• Molecular therapies offer a promising new avenue for ADPKD treatment.
• Vasopressin receptor antagonists and somatostatin analogs are key drug classes under investigation.
• Further clinical evidence is needed to establish efficacy and safety in human patients.